A study conducted by the University of Barcelona and the Hospital del Mar Medical Research Institute, and published in the prestigious New England Journal of Medicine has found that in rare cases, drugs used to aid in the treatment of osteoporosis, actually create an increased risk of femoral bone fractures in certain patients. The agents called bisphosphonates are routinely and successfully used as a treatment for osteoporosis, but actually have a negative effect on patients with a certain type of genetic mutation.
- Some bone density treatments do not work, and also potentially put patient’s at further risk for fractures despite claims of helping increase density.
- There is a rare genetic disposition being studied that may prove the atypical fractures are not from the drugs, but from genetics.
- The gene study is trying to prove that it is most beneficial for research to be done on everyone with Osteoporosis that way their risk for atypical fracture is known before being given treatment.
“A team of researchers of the University of Barcelona and the Hospital del Mar Medical Research Institute (IMIM) have discovered a new mutation that has an impact on the bone so that it is vulnerable to the bisphosphonate, a drug used to treat osteoporosis.”